Biomarker ID | 387 |
PMID | 18948370 |
Year | 2008 |
Biomarker | Serum PSA + DRE + Methylation Status of APC |
Biomarker Basis | Methylation Based |
Biomolecule | mRNA |
Source | Expressed Prostatic Secretion |
Subjects | Humans |
Regulation | Hypermethylated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | OR = 0.005 (95% CI: 0–1.156) |
Effect on Pathways | Pathways Include:-ATM-dependent DNA damage response,Nuclear beta-catenin signaling and target gene transcription regulation,Degradation of beta-catenin by the destruction complex,Signaling events mediated by hepatocyte growth factor receptor (c-Met),MAPK cascade role in angiogenesis |
Experiment | (Benign Samples + Gleason sums < 7) Vs ≥ 7 |
Type of Biomarker | Diagnostic |
Cohort | Of the 74 specimen cohort, only the 63 that yielded >300 ng total nucleic acid were used for DNA methylation analysis. Patients with Benign + Gleason sum <7 (n = 52) and Gleason sum >7 (n = 11) were chosen as the cohort. |
Senstivity | NA |
Specificity | NA |
AUC | 0.754 (95% CI: 0.616–0.892) |
Accuracy | NA |
Level Of Significance | p<0.01 |
Method Used | methylation-sensitive TaqMan QPCR |
Clinical | No |
Remarks | For Analysis, Serum PSA, plus Digital rectal Exam plus a marker was chosen for analysis and compared to whether they improved performance over analysis done by only Serum PSA + DRE |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | APC |